In Friday’s Wall Street session, UroGen Pharma Ltd (NASDAQ:URGN) shares traded at $7.31, down -25.79% from the previous session.
URGN stock price is now -31.10% away from the 50-day moving average and -37.83% away from the 200-day moving average. The market capitalization of the company currently stands at $337.05M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $23, Scotiabank recently initiated with Sector Outperform rating for UroGen Pharma Ltd (NASDAQ: URGN). , while ‘Guggenheim’ rates the stock as ‘Buy’
In other news, Schoenberg Mark, Chief Medical Officer sold 4,551 shares of the company’s stock on Jan 31 ’25. The stock was sold for $50,698 at an average price of $11.14. Upon completion of the transaction, the Chief Medical Officer now directly owns 145,666 shares in the company, valued at $1.06 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 31 ’25, General Counsel Smith Jason Drew sold 7,379 shares of the business’s stock. A total of $82,202 was realized by selling the stock at an average price of $11.14. This leaves the insider owning 26,468 shares of the company worth $0.19 million. A total of 17.09% of the company’s stock is owned by insiders.
During the past 12 months, UroGen Pharma Ltd has had a low of $8.94 and a high of $20.70. The fifty day moving average price for URGN is $10.6102 and a two-hundred day moving average price translates $11.758875 for the stock.
The latest earnings results from UroGen Pharma Ltd (NASDAQ: URGN) was released for 2025-03-31. The company reported revenue of $20.25 million for the quarter, compared to $18.78 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.84 percent.
